Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.71 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.66 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900512 | 1.00 | PARP1 (1.00) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL1586541 | 0.95 | PARP1 (0.91) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL28598382 | 0.94 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL22857122 | 0.94 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL30176861 | 0.94 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL30176973 | 0.94 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL14621928 | 0.94 | PARP1 (0.89) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL5794718 | 0.90 | PARP1 (0.82) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL29431542 | 0.90 | PARP1 (0.82) | PARP1TNKS2PDE10APARP2KMT2A | |
| SCHEMBL16404338 | 0.87 | PDE10A (0.84) | PARP1TNKS2PDE10APARP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010671-B | One-step synthesis method of 2-substituted quinazolinone | 江苏大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-112174899-B | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2023-01-17 | — | — | CN | disclosed |
| CN-115010671-A | One-step synthesis method of 2-substituted quinazolinone | 江苏大学 | 2022-09-06 | — | — | CN | disclosed |
| CN-109384731-B | Method for preparing quinazolinone from enol | 南京理工大学 | 2021-10-08 | — | — | CN | disclosed |
| CN-112174899-A | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2021-01-05 | — | — | CN | disclosed |
| CN-109384731-A | A method of quinazolinone is prepared by enol | 南京理工大学 | 2019-02-26 | — | — | CN | disclosed |
| CN-103228141-B | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-20 | — | — | CN | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-6004979-A | ANGIOTENSIN II INHIBITORS; 4-((CARBOXY)ARYLOXY)-QUINOLINE DERIVATIVES | HOECHST MARION ROUSSEL (FR) | 1999-12-21 | — | — | US | disclosed |
| US-5817674-A | ANTIOTENSIN II RECEPTOR ANTAGONISTS | ROUSSEL UCLAF (FR) | 1998-10-06 | — | — | US | disclosed |
| US-5350752-A | Dihydropyrimidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1994-09-27 | — | — | US | disclosed |
| US-5234923-A | SUBSTITUTE INDOLE AND BENZIMIDAZOLE DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0547442-A1 | Dihydropyrimidin derivatives used as A-II receptor antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0547827-A1 | Indole and benzimidazole-substituted dihydropyrimidine derivatives useful as A-II receptors antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0547556-A1 | Substituted indole and benzimidazole derivatives useful as A-II receptors antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5212177-A | INDOLE AND BENZIMIDAZOLE-SUBSTITUTED DIHYDROPYRIMIDINE DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0498723-A1 | Nitrogen containing bicycle compounds, method for their preparation, their use as pharmaceutical and compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
| EP-0407342-A2 | Pyrimidine derivatives | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | PARP1 2030/4885TNKS2 3993/4885PDE10A 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.